Anti-CD19 anti-CD20 bispecific chimeric antigen receptor T cell therapeutics - Beijing Doing Biomedical

Drug Profile

Anti-CD19 anti-CD20 bispecific chimeric antigen receptor T cell therapeutics - Beijing Doing Biomedical

Alternative Names: anti-CD19 anti-CD20 bispecific CAR-T cells

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Doing Biomedical
  • Class CAR-T cell therapies
  • Mechanism of Action CD19 antigen inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 08 Sep 2017 Preclinical trials in Haematological malignancies in China before September 2017 (Parenteral)
  • 08 Sep 2017 Beijing Doing Biomedical plans a phase I trial for Haematological malignancies (Second-line therapy or greater) (NCT03271515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top